<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848833</url>
  </required_header>
  <id_info>
    <org_study_id>1245.116</org_study_id>
    <nct_id>NCT02848833</nct_id>
  </id_info>
  <brief_title>JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE速 (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type
      2 diabetes mellitus in a routine clinical practice setting
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Actual">April 17, 2020</completion_date>
  <primary_completion_date type="Actual">April 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All reported adverse events in patients who take at least one dose of JARDIANCE速 will be noted.</measure>
    <time_frame>24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c after 12 weeks and/or 24 weeks of treatment</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3385</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>JARDIANCE</arm_group_label>
    <description>T2DM with JARDIANCE</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JARDIANCE 10mg</intervention_name>
    <description>T2DM with JARDIANCE 10mg</description>
    <arm_group_label>JARDIANCE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JARDIANCE 25mg</intervention_name>
    <description>MT2DM with JARDIANCE 25mgax</description>
    <arm_group_label>JARDIANCE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetes mellitus in Korea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients who have been started on JARDIANCE速 in accordance with the approved label in
             Korea

          2. Age = 19 years at enrolment

          3. Patients who have signed on the data release consent form

        Exclusion criteria:

          1. Known hypersensitivity to empagliflozin or any of its excipients

          2. Patients with type 1 diabetes or for the treatment of diabetic ketoacidosis

          3. Patients with persistent estimated Glomerular Filtration Rate &lt;60 mL/min/1.73 m2,end
             stage renal disease or on dialysis

          4. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption

          5. Patients for whom empagliflozin is contraindicated according local label of JARDIANCE速
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

